777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 12,463
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman | 7M | N/A | 1953 |
Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 6.59M | N/A | 1960 |
Mr. Robert E. Landry Jr. | Executive VP of Finance & CFO | 1.84M | 11.1M | 1964 |
Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research | 1.62M | 19.39M | 1959 |
Mr. Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply | 1.95M | 45.28M | 1973 |
Ms. Marion E. McCourt | Executive Vice President of Commercial | 1.5M | 4.25M | 1960 |
Ms. Patrice Gilooly | Senior Vice President of Quality Assurance & Operations | N/A | N/A | N/A |
Mr. Christopher R. Fenimore CPA | Senior VP, Head of Accounting & Controller | N/A | N/A | 1971 |
Mr. Gerald Underwood | Senior Vice President of Technical Operations | N/A | N/A | N/A |
Mr. Bob McCowan | Senior VP of IT & Chief Information Officer | N/A | N/A | N/A |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Regeneron Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 December 2023 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 10; Compensation: 9.